Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats

Toxicological Sciences

Volumn 97, Issue 1, 2007, Pages 214-221

  Lim, Steven T S ^a   Dragull, Klaus ^b   Tang, Chung Shih ^b   Bittenbender, Harry C ^b   Efird, Jimmy T ^a   Nerurkar, Pratibha V ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII AT MANOA   (United States)

Author keywords

Cytochrome P450; Kava; Kavalactones; Oxidative stress; Pipermethystine

Indexed keywords

ACETONE; ALKALOID; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; DESMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; GLUTATHIONE; KAVA EXTRACT; KAWAIN; LACTONE DERIVATIVE; LIPID; MALONALDEHYDE; MESSENGER RNA; METHYSTICIN; PIPERMETHYSTINE; PLANT MEDICINAL PRODUCT; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WATER; YANGONIN; CYP1A2 PROTEIN, RAT; CYTOCHROME P450 2D6; KAVA; LACTONE; PLANT EXTRACT; PYRIDONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; LIPID PEROXIDATION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PIPER METHYSTICUM; PLANT ROOT; PROTEIN EXPRESSION; RAT; RAT STRAIN; TOXICITY TESTING; ANIMAL; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; FISCHER 344 RAT; GENETICS; ISOLATION AND PURIFICATION; LIVER; LIVER MITOCHONDRION; METABOLISM; PLANT LEAF; RHIZOME; TIME; UPREGULATION;

PIPER METHYSTICUM; RATTUS;

ALKALOIDS; ANIMALS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; GLUTATHIONE; KAVA; LACTONES; LIVER; MALE; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; PLANT EXTRACTS; PLANT LEAVES; PYRIDONES; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES; RHIZOME; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 34347232391     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm035     Document Type: Article

References (40)

1. Anke, J., and Ramzan, I. (2004). Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J. Ethnopharmacol. 93, 153-160.
2. Caro, A. A., and Cederbaum, A. I. (2004). Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 44 27-42.
3. Clayton, N. P., Yoshizawa, K. Y., Kissling, G. E., Burka, L. T., Chan, P.-C., and Nyska, A. (2007). Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol. 58, 223-236; Epub 2006 Oct 23.
4. Clouatre, D. L. (2004). Kava kava: Examining new reports of toxicity. Toxicol. Lett. 150, 85-96.
5. Clough, A. (2003). Enough! or too much. What is 'excessive' kava use in Arnhem Land? Drug Alcohol. Rev. 22, 43-51.
6. Clough, A. R., Bailie, R. S., and Currie, B. (2003a). Liver function test abnormalities in users of aqueous kava extracts. J. Toxicol. Clin. Toxicol. 41, 821-829.
7. Clough, A. R., Jacups, S. P.,Wang, Z., Burns, C. B., Bailie, R. S., Cairney, S. J., Collie, A., Guyula, T., McDonald, S. P., and Currie, B. J. (2003b). Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern. Med. J. 33, 336-340.
8. Clough, A. R., Rowley, K., and O'Dea, K. (2004). Kava use, dyslipidaemia and biomarkers of dietary quality in Aboriginal people in Arnhem Land in the Northern Territory (NT), Australia. Eur. J. Clin. Nutr. 58 1090-1093.
9. Denham, A., McIntyre, M., and Whitehouse, J. (2002). Kava - the unfolding story: Report on a work-in-progress. J. Altern. Complement. Med. 8, 237-263.
10. Dragull, K., Yoshida, W. Y., and Tang, C. S. (2003). Piperidine alkaloids from Piper methysticum. Phytochemistry 63, 193-198.
11. Folmer, F., Blasius, R., Morceau, F., Tabudravu, J., Dicato, M., Jaspars, M., and Diederich, M. (2006). Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 71, 1206-1218.
12. Haddad, J. J. (2004). Oxygen sensing and oxidant/redox-related pathways. Biochem. Biophys. Res. Commun. 316, 969-977.
13. Hissin, P. J., and Hilf, R. (1976). A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 74, 214-226.
14. Imaoka, S., Osada, M., Minamiyama, Y., Yukimura, T., Toyokuni, S., Takemura, S., Hiroi, T., and Funae, Y. (2004). Role of phenobarbital-inducible cytochrome P450s as a source of active oxygen species in DNA-oxidation. Cancer Lett. 203, 117-125.
15. Keledjian, J., Duffield, P. H., Jamieson, D. D., Lidgard, R. O., and Duffield, A. M. (1988). Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J. Pharm. Sci. 77 1003-1006.
16. Koch, O. R., Pani, G., Borrello, S., Colavitti, R., Cravero, A., Farre, S., and Galcotti, T. (2004). Oxidative stress and antioxidant defenses in ethanol induced liver injury. Mol. Aspects Med. 25, 191-198.
17. Kono, H., Fujii, H., Amemiya, H., Asakawa, M., Hirai, Y., Maki, A., Tsuchiya, M., Matsuda, M., and Yamamoto, M. (2005). Role of Kupffer cells in lung injury in rats administered endotoxin 1. J. Surg. Res. 129, 176189.
18. Lebot, V., Merlin, M. D., and Lindstrom, L. (1997). Kava - The Pacific Elixir: The Definitive Guide to Its Ethnobotany, History, and Chemistry. Healing Arts Press, Rochester, VT.
19. Mathews, J. M., Etheridge, A. S., and Black, S. R. (2002). Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 30, 1153-1157.
20. Mathews, J. M., Etheridge, A. S., Valentine, J. L., Black, S. R., Coleman, D. P., Patel, P., So, J., and Burka, L. T. (2005). Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos. 33, 1555-1563.
21. Nelson, A. C., Huang, W., and Moody, D. E. (2001). Variables in human liver microsome preparation: Impact on the kinetics of 1-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. Drug Metab. Dispos. 29, 319-325.
22. Nerurkar, P. V., Dragull, K., and Tang, C. S. (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol. Sci. 79, 106-11.
23. O'Sullivan, H. M., and Lum, K. (2004). The poisoning of 'awa: The non-traditional use of an ancient remedy. Pac. Health Dialog 11 211-215.
24. Pon, L. A., and Schon, E. A. (2001). Mitochondria. Methods Cell Biol. 65, 13-18.
25. Rasmussen, A. K., Scheline, R. R., Solheim, E., and Hansel, R. (1979). Metabolism of some kava pyrones in the rat. Xenobiotica 9, 1-16.
26. Regula, K. M., Ens, K., and Krishenbaum, L. A. (2003). Mitochondria-assisted cell suicide: A license to kill. J. Mol. Cell. Cardiol. 35, 559-567.
27. Rojo, A. I., Salinas, M., Martin, D., Perona, R., and Cuadrado, A. (2004). Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J. Neurosci. 24, 7324-7334.
28. Russmann, S., Barguil, Y., Cabalion, P., Kritsanida, M., Duhet, D., and Lauterburg, B. H. (2003). Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. 15, 1033-1036.
29. Russmann, S., Lauterburg, B. H., and Helbling, A. (2001). Kava hepatotoxicity. Ann. Intern. Med. 135, 68-69.
30. Schmidt, M. (2003). Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. J. Altern. Complement. Med. 9, 183-187; author reply 187-188.
31. Schmidt, M., Nahrstedt, A., and Lupke, N. P. (2002). Piper methysticum (kava) under discussion: Observations on quality, effectiveness and safety. Wien. Med. Wochenschr. 152, 382-388.
32. Singh, Y. N., and Devkota, A. K. (2003). Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 69, 496-499.
33. Singh, Y. N., and Singh, N. N. (2002). Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16, 731-743.
34. Sorrentino, L., Capasso, A., and Schmidt, M. (2006). Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine 13, 542-549.
35. Unger, M., Holzgrabe, U., Jacobsen,W., Cummins, C., and Benet, L. Z. (2002). Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 68, 1055-1058.
36. Wang, X.-Z., Zhang, S.-J., Chen, Y.-X., Chen, Z.-X., Huang, Y.-H., and Zhang, L.-J. (2004). Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. World J. Gastroenterol. 10, 2706-2710.
37. Wu, D., and Cederbaum, A. I. (2005). Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1. Toxicol. Appl. Pharmacol. 207, 70-76.
38. Zou, L., Harkey, M. R., and Henderson, G. L. (2002). Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71, 1579-1589.
39. Zou, L., Harkey, M. R., and Henderson, G. L. (2005). Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion. Planta Med. 71, 142-146.
40. Zou, L., Henderson, G. L., Harkey, M. R., Sakai, Y., and Li, A. (2004). Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 11, 285-294.